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Preeclampsia (PE) is a pregnancy-specific disorder characterized by
hypertension and proteinuria after 20 wk gestation. Abnormal
extravillous trophoblast (EVT) invasion and remodeling of uterine
spiral arterioles is thought to contribute to PE development.
Interleukin-11 (IL11) impedes human EVT invasion in vitro and is
elevated in PE decidua in women. We demonstrate that IL11 admin-
istered to mice causes development of PE features. Immunohisto-
chemistry shows IL11 compromises trophoblast invasion, spiral
artery remodeling, and placentation, leading to increased systolic
blood pressure (SBP), proteinuria, and intrauterine growth re-
striction, although nonpregnant mice were unaffected. Real-time
PCR array analysis identified pregnancy-associated plasma protein
A2 (PAPPA2), associated with PE in women, as an IL11 regulated
target. IL11 increased PAPPA2 serum and placental tissue levels in
mice. In vitro, IL11 compromised primary human EVT invasion,
whereas siRNA knockdown of PAPPA2 alleviated the effect. Genes
regulating uterine natural killer (uNK) recruitment and differenti-
ation were down-regulated and uNK cells were reduced after IL11
treatment in mice. IL11 withdrawal in mice at onset of PE features
reduced SBP and proteinuria to control levels and alleviated placental
labyrinth defects. In women, placental IL11 immunostaining levels
increased in PE pregnancies and in serum collected from women
before development of early-onset PE, shown by ELISA. These results
indicate that elevated IL11 levels result in physiological changes at the
maternal–fetal interface, contribute to abnormal placentation, and
lead to the development of PE. Targeting placental IL11 may provide
a new treatment option for PE.
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Preeclampsia (PE) is a pregnancy-induced disorder charac-terized by hypertension and proteinuria, unique to humans,
affecting ∼8% of pregnancies (1). The etiology is poorly un-
derstood (2); nevertheless, there is substantial evidence showing
abnormal placentation is the key underlying cause. During
pregnancy, highly invasive extravillous trophoblasts (EVT) ac-
quire vascular-like properties to remodel uterine spiral arteri-
oles. This creates low-resistance, large-diameter vessels that
promote uteroplacental blood supply to sustain fetal growth (3,
4). It is widely accepted that inadequate trophoblast invasion and
impaired uterine spiral artery remodeling is an initiating factor in
the development of PE (5). This is thought to impair uteroplacental
arterial flow and lead to placental oxidative stress (6). PE is asso-
ciated with increased placental secretion of proinflammatory
cytokines (7) and angiogenic regulators (8), thought to contrib-
ute to widespread maternal endothelial dysfunction. The clinical
symptoms of PE are hypertension, proteinuria, and peripheral
and/or cerebral edema. Symptoms can differentially manifest
during the second (early-onset, EO), or third (late-onset, LO) tri-
mester (9). In addition to the maternal symptoms, PE is also fre-
quently associated with prematurity (1) and intrauterine growth
restriction (IUGR), related to impaired insulin-like growth factor
(IGF1) signaling (10).
It is well established that cytokines produced within the local
uterine environment can alter trophoblast action (11). Interleukin-
11 (IL11) is a pleiotropic cytokine that regulates cell cycle, invasion,
and migration in numerous cell types (12, 13), all roles critical to
placental development. IL11 is a member of the IL-6-type cytokines
and signals via the IL11 receptor (R) α chain and signal transducer
gp130 (14) to activate the Janus kinase (JAK)/Signal transducers
and activators of transcription (STAT)3 pathway in human endo-
metrium (15) and primary human EVT (16, 17). IL11 is required
for decidualization in humans (18) and mice (19). IL11 levels are
elevated in PE decidual tissue (20). More recently, IL11 has been
shown to impede human EVT invasion in vitro (16, 21), although
its function in placentation in vivo has not been investigated.
We investigated the effect of elevated IL11 levels on placen-
tation and PE features in mice. We demonstrated that IL11
contributes to impaired trophoblast invasion, spiral artery remod-
eling, and altered placental labyrinth morphology, leading to the
development of PE-like features including elevated systolic
blood pressure (SBP), proteinuria, kidney glomerular pathology,
and IUGR. We identified IL11 as a potential valuable biomarker
that could anticipate the development of PE in women. Finally,
we demonstrated that IL11 withdrawal after the onset of PE
features in mice could rescue PE features. Thus, we identify IL11
as a key regulator of EVT invasion during early gestation in mice
and provide evidence that dysregulation of IL11 could contribute
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to PE development in women. This suggests that targeting IL11
may provide a new treatment option for PE.
Results
IL11 Administration Impairs EVT Invasion and Spiral Artery Remodeling
in Vivo. In vivo evidence for a functional role of IL11 in placen-
tation is lacking. We localized IL11 and IL11Rα in the mouse
placental endovascular trophoblast and endothelial cells in im-
plantation sites throughout gestation (Fig. 1 A and B) and de-
termined mRNA and protein expression levels (Fig. S1). This
reflects localization patterns in women (Fig. S2), implying a role in
placentation in vivo. To model elevated levels of IL11 as in women
with PE (20), mice were administered with physiologically relevant
doses of IL11 (Fig. S3) or saline vehicle control twice daily from
embryonic day (E)8 through E13 to determine effects on spiral
artery remodeling and placentation (22), or E10 through E17 to
determine effects on PE features. At E13, IL11 enhanced phos-
phorylated (p) STAT3 in the placental labyrinth and maternal
spiral arterioles, suggesting that STAT3 is one of the signaling
pathways that mediate IL11 action at these sites (Fig. S3). Ele-
vated IL11 did not alter the expression of IL11Rα in the mouse
placenta (Fig. S3). Control implantation sites at E13 showed de-
cidual trophoblast invasion and displacement of α-smooth muscle
actin (α-SMA) positive vascular smooth muscle cells (VSMCs),
indicating normal spiral artery remodeling (Fig. 1 C andD and Fig.
S4). In IL11-treated mice, trophoblast invasion and spiral artery
remodeling was impaired, decidual vessel area was significantly
reduced, and VSMCs lining decidual spiral arterioles were retained
(Fig. 1 C and D and Fig. S4), supporting in vitro findings in humans
(16, 21). Because IL11 plays a crucial role in decidualization from
E3 through E6 (19), we investigated the effect of elevated IL11
during mid gestation on the decidua. In mice treated with IL11 from
E8 through E13, vimentin and desmin immunostaining (decidual
markers) were unchanged between groups (Fig. 1 E and F and
Fig. S4).
IL11 Administration Recapitulates the Features of PE in Mice. IL11
impaired trophoblast invasion in vivo; thus, we determined the
effect of elevated IL11 on hallmark features of PE in mice. In
pregnant mice treated with IL11 from E10 through E17, SBP
increased by 20% at E15 (116.20 mm/Hg ± 2.37 versus control
92.96 mm/Hg ± 1.85, P < 0.001) (Fig. 1G). IL11 had no effect on
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Fig. 1. IL11 and IL11Rα localize to mouse placental
trophoblasts and vasculature, and IL11 administra-
tion during pregnancy in mice alters placentation
and contributes to maternal and fetal features of PE
in mice. (A) Representative photomicrographs of
wild-type mid-gestation (E13) implantation site sec-
tions immunostained for IL11 (n = 3 mice/time-
point). (i) IL11 localized to labyrinth mononuclear
trophoblasts (arrow) associated with maternal blood
sinuses, (ii) labyrinth fetal capillary endothelial cells
(asterisk), (iii) spongiotrophoblast glycogen tropho-
blasts, and (iv) trophoblast giant cells at the mater-
nal−fetal interface. [Scale bar: 100 μm (i) and 50 μm
(ii−iv).] (B, i) IL11Rα was produced abundantly
throughout the decidua and placenta, specifically
within (ii) decidual EVTs (arrow), (iii) glycogen tro-
phoblasts, (iv) labyrinth trophoblasts, and (v) fetal
capillary endothelial cells (asterisk). [Scale bar: 200 μm
(i), 50 μm (ii−iv), and 20 μm (v).] Nonpregnant or
pregnant mice were treated with saline vehicle
control or IL11 (500 μg·kg−1·d−1) from E8 through
E13 (n = 5) or E10 through E17, or 8-d equivalent in
nonpregnant mice (n = 8). (C ) E13 embryo sections
were stained for trophoblasts (cytokeratin; red) or
smooth muscle (α-SMA; green). (Scale bar: 50 μm.)
(D) Decidual vessel area was measured in placental
cross sections at E13. Data are mean ± SEM, Students
t test, ***P < 0.001, n = 5. (E) Vimentin immunos-
taining highlights decidual area at E13. (Scale bar:
200 μm.) (F) Staining intensity was quantified as
pixel intensity/area (percent). Data are mean ± SEM,
n = 5. (G) SBP was measured by tail cuff plethys-
mography. Data are mean ± SEM, one-way ANOVA,
*P < 0.05, ***P < 0.001, n = 8. (H) Circulating s-Flt1
levels were quantified by ELISA in mouse sera. Data
are mean ± SEM, one-way ANOVA, **P < 0.01, n = 5.
(I) Total urinary protein was quantified by Bradford
colorimetric assay. Data are mean ± SEM, Students t
test, **P < 0.01, n = 5. (J) Glomerular pathology at
E17, including narrow glomerular capillary lumen (L) and basement membrane thickening (asterisk) shown by electron microscopy at high power magnifi-
cation, 8000×. (K) Glomerular basement membrane thickening was quantified across all treatment groups. Data are mean ± SEM, one-way ANOVA, ***P <
0.001, n = 8. (L) Haematoxylin and eosin (H&E; Top) staining shows abnormal labyrinth structure following IL11 administration at E17. Masson’s trichrome
staining (MTC; Middle) shows collagen deposition (arrow heads). Isolectin B4 (ISB4; Bottom) highlights maternal sinusoid branches. Labyrinth vascular
branching development is impaired (arrow head) in IL11-treated mice. Inset is negative control. (Scale bar: 200 μm.) (M) Number of labyrinth vascular
branches were counted, expressed as branches per placental area (square millimeters). Data are mean ± SEM, Students t test, **P < 0.01, ****P < 0.0001, n =
8. (N) Representative photos of (O); fetal weight (E17) was reduced following IL11 or PEGIL11 treatment compared with saline or PEG control, respectively.
Data are mean ± SEM, Students t test, ****P < 0.0001, n = 8. (P) Representative photomicrographs of E17 PEG-treated implantation site immunostained for
PEG, localized to mouse placental trophoblasts (arrow in Bottom Left) but not fetal tissue (Bottom Right). [Scale bar: 500 μm (Top) and 100 μm (Bottom panels).]
Inset is negative control.
Winship et al. PNAS | December 29, 2015 | vol. 112 | no. 52 | 15929
D
EV
EL
O
PM
EN
TA
L
BI
O
LO
G
Y
SBP in nonpregnant mice. The antiangiogenic factor soluble (s)-
Flt1, associated with endothelial dysfunction and PE in mice and
women (23), was increased in a pregnancy-specific manner in
response to IL11 at E13 (46,455 pg/mL ± 10,836 versus control
18,750 pg/mL ± 2,723, P < 0.01) (Fig. 1H). IL11 treatment from
E10 through E17 increased urinary protein in pregnant mice at
middle and late gestation (117.4 μg/μL ± 5.86 versus control
65.64 μg/μL ± 12.38, P < 0.001) (Fig. 1I). Kidney glomeruli from
IL11-treated pregnant mice were enlarged and ischemic com-
pared with pregnant controls (Fig. S3). Glomeruli had narrow
capillary lumen and thickened basement membrane that facili-
tates filtration (Fig. 1 J and K), suggesting endotheliosis and
extracellular matrix deposition in the maternal kidneys.
IL11 Impairs Placental Labyrinth Vasculature Development and Promotes
IUGR via Placental Insufficiency. Elevated IL11 dramatically altered
placental labyrinth structure and morphology at mid and late ges-
tation compared with control (Fig. 1L and Fig. S5), which may alter
maternal−fetal exchange (22). We demonstrated impaired labyrinth
endothelial cell differentiation (Mest) and reduced invasive tro-
phoblasts (Prlb) at the maternal−fetal interface (Fig. S5). Labyrinth
fetal vascular branching (Isolectin B4) was significantly reduced
(Fig. 1 L and M) and collagen deposition was evident in IL11-
treated placenta compared with control at E17 (Fig. 1L). IL11 re-
duced fetal weight at E17 (0.63g ± 0.02 versus control 0.87g ± 0.01,
P < 0.01) (Fig. 1 N and O). To confirm that IL11 likely acts via the
placenta and not directly on the fetus to cause IUGR, polyethylene
glycol (PEG) was ligated to IL11. Very little PEGIL11 crossed the
placenta (Fig. 1P and Fig. S6). PEGIL11 resulted in a similar re-
duction in fetal weight to IL11 alone, compared with respective
controls (Fig. 1O). We identified IGF1, an important regulator of
placental and fetal growth (10), as an IL11 regulated target in
the mouse placenta at mid-gestation. IL11 down-regulated IGF1
mRNA by 2.05-fold at E13 (P < 0.01) (Fig. 2A) and significantly
reduced serum IGF1 levels at E17 (Fig. 2B).
IL11 Impedes Human EVT Invasion via the Pregnancy-Associated
Plasma Protein A2 Protease. We identified IL11 targets in the
mouse placenta at E13 by quantitative PCR (qPCR) array. IL11 up-
regulated three genes, and down-regulated four genes (>twofold)
(Fig. 2A). Pregnancy-associated plasma protein A2 (PAPPA2) was
up-regulated 2.6-fold (P < 0.001). PAPPA2 protein is elevated in
EO PE placenta (24) and maternal serum before PE onset (25) and
expressed by first-trimester EVT in women and by invasive tro-
phoblasts in mice (26). However, the functional role of PAPPA2 in
EVT invasion is not known. IL11 regulated PAPPA2 mRNA and
protein in mouse EVTs and decidual cells and in IL11-treated
mouse serum, in a pregnancy-specific manner (Fig. 2 C and D and
Fig. S7). IL11 regulated PAPPA2 protein in human placental villous
cytotrophoblast and syncytiotrophoblast (Fig. 2 E and F). In first-
trimester placental explants, PAPPA2 reduced trophoblast out-
growth by 55% ± 8% compared with control (P < 0.05), to a similar
extent as did IL11 (Fig. 2 G and H). Knockdown of endogenous
PAPPA2 (Fig. S7) did not significantly alter outgrowth (P > 0.05)
(Fig. 2H), suggesting that only abnormally elevated PAPPA2 levels
alter trophoblast invasion. PAPPA2 knockdown rescued IL11-
impaired trophoblast outgrowth (79% ± 6%) compared with
IL11 (50% ± 4%, P < 0.05) (Fig. 2H).
IL11 Alters Decidual Immune Cells Required for Normal Spiral Artery
Remodeling. Immune cells function at the maternal−fetal in-
terface to mediate maternal tolerance and facilitate decidual and
arterial tissue remodeling during EVT invasion (27). IL11 re-
duced placental gene expression of IL10, IL15, and IL18 (Fig.
2A), which play important roles in regulating decidual immune
cell functions. As indicated by DBA lectin staining (Fig. 2I), IL11
dramatically reduced the number of decidual uterine natural
killer (uNK) cells at mid-gestation (17 ± 2 versus control 50 ± 3,
P < 0.0001) (Fig. 2J) and also promoted a significant increase in
the number of senescent binucleate decidual uNK cells (P <
0.05) (Fig. 2K). We found a trend in reduced decidual macro-
phages (Fig. S4), although this was not significant.
IL11 Withdrawal After Onset of PE Features in Mice Rescues the
Placenta and Alleviates PE Hallmarks. Our data suggest that IL11
contributed to the pathogenesis of PE features in mice via pla-
cental alterations. We investigated normalizing elevated IL11
levels during pregnancy in mice, in particular, after the onset of
placental dysfunction/PE features. Mice received IL11 from E10
through E14 so that administration was ceased at the onset of
IL11-induced PE features. By late gestation, IL11 withdrawal
restored IL11-induced elevated SBP in pregnant mice to control
levels (withdrawal 100.21 mm/Hg ± 1.32 versus IL11 117.65 mm/Hg ±
1.89, P < 0.0001) (Fig. 3A). Proteinuria was alleviated (with-
drawal 50.22 μg/μL ± 10.75 versus IL11 121.20 μg/μL ± 2.53, P <
0.001) (Fig. 3B), and kidney glomerular hypertrophy seen in
pregnant IL11-treated mice subsided (Fig. S8). Fetal weight by
E17 was significantly increased by 18% (withdrawal 0.72 g ± 0.04
versus IL11 0.61 g ± 0.04, P < 0.05) (Fig. 3C). To determine how
quenching midlate gestation elevations in IL11 may ameliorate
PE features after their onset, we examined implantation sites
from IL11 treated and IL11 withdrawal mice at E17. IL11
withdrawal did not rescue IL11-impaired spiral artery remodel-
ing (Fig. 3 D and E). However, differences in placental labyrinth
morphology were evident in the IL11 withdrawal group com-
pared with IL11-treated mice at E17 (Fig. 3D). The IL11 with-
drawal labyrinth morphology resembled the control (Fig. 3D).
Isolectin B4 staining highlighted impaired labyrinth branching and
structure in IL11-treated placenta but normal branching in the
IL11 withdrawal placenta (Fig. 3 D and F). We investigated the
potential for IL11 to modify syncytialization, because the syn-
cytium is the barrier between the maternal and fetal circulations
in the human and mouse placenta. However, IL11 had no affect
on Syna in the mouse placenta (Fig. S5) or syncytins SYN1,
SYN2, or E-CADHERIN gene transcription, or human chorionic
gonadotrophin (hCG) protein secretion in primary human first-
trimester placental explants (Fig. S9). IL11 withdrawal alleviated
IL11-induced STAT3 activation in the mouse placenta (Fig. S8).
Quantitative gene array analysis was performed on E17 placental
tissue samples from mice administered with IL11 or saline from
E10 through E17 or E10 through E14 (IL11 withdrawal group).
Placental growth factor (PLGF) showed a 2.2-fold increase and
follistatin-like-3 (FSTL3) showed a twofold decrease in the IL11
withdrawal mouse placenta compared with IL11-treated mice at
E17 (P < 0.05) (Fig. 3G).
IL11 in PE in Women and the Potential to Target IL11. Circulating
IL11 was significantly increased in women with EO PE (35.48 pg/
mL ± 6.29) compared with LO PE (9.77 pg/mL ± 0.58) or nor-
mal pregnant gestation-matched controls (4.83 pg/mL ± 1.88)
before PE development (P < 0.001) (Fig. 4A) and also following
diagnosis (P < 0.01) (Fig. 4B) (Table S1). In PE placenta, there
was a trending increase in IL11 and IL11Rα mRNA expression
(Fig. 4C), and IL11 protein was significantly up-regulated (Fig. 4
D and E). IL11 immunostaining was increased in syncytio-
trophoblast and cytotrophoblast (Fig. 4D).
Discussion
Our data answer an outstanding question regarding the role of
IL11 in trophoblast invasion and placental development in vivo.
Evidence for a functional role of IL11 in placentation in vivo was
lacking. Female IL11Rα−/− mice are infertile (19), attributed to
defective decidualization between E3 and E6, leading to mid-
gestation pregnancy loss (28), and thus are not a useful model for
studying placentation. This is the first study, to our knowledge, to
demonstrate that IL11 is causal of PE features in a mouse model.
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Defective decidual trophoblast invasion, spiral artery remodel-
ing, and placental labyrinth development were associated with
IL11 elevation in mice. Moreover, IL11-administered pregnant
mice exhibit diagnostic criteria for PE, including elevated SBP,
sFlt-1 dysregulation, and proteinuria with kidney pathology. Our
data suggest that elevated SBP and proteinuria can be reversed
after damage to the placenta, vasculature, and the kidney has
ensued, whereas totally reversing abnormal EVT invasion is not
necessary in this model. Furthermore, IL11 is elevated in the serum
of women with EO PE before diagnosis and disease onset, strongly
suggesting that IL11 is up-regulated early during placentation be-
fore PE. IL11 is therefore a likely causal factor of PE in women.
Similar to IL11-treated mice that exhibit impaired embryo growth,
EO PE in women is almost always associated with IUGR.
Nonpregnant female mice administered with IL11 did not
develop PE features. These data demonstrate a pregnancy-spe-
cific effect of IL11 in eliciting PE features in mice, strongly
suggesting this occurs via placental alterations. Administration of
PEGIL11 confirmed at least that the IUGR phenotype seen in
IL11-treated mice was attributed to placental insufficiency and
not to direct IL11 signaling in fetal tissues. PEGIL11 did not
cross the placenta, likely due to the large hydrodynamic volume
displayed by the PEG moiety. This finding in itself is novel,
suggesting that PEGylation of potential pharmacological thera-
peutics may reduce potential embryotoxic effects in pregnancy.
In accordance with IUGR, IL11-treated mice exhibited placental
fibrosis, associated with placental insufficiency and IUGR in women
(29). We identified that IL11 reduced placental gene expression and
circulating protein levels of IGF1, an important regulator of pla-
cental and fetal growth (10), suggesting a mechanism by which IL11
contributes to IUGR via the placenta. Interestingly, IGF1 itself can
also alter trophoblast migration (30).
We highlighted a role for exogenous IL11 activating STAT3 in
the human and mouse placenta. Other pathways activated by
IL11 include the mitogen-activated protein kinase (31), Src-family
kinases (32), and phosphatidylinositol 3-kinase signaling pathways
(33). The relative importance of each signaling pathway is tissue-
specific (34). Our results are consistent with previous findings in fe-
male reproductive tissues, where IL11 has been shown to signal ex-
clusively via the JAK/STAT3 pathway in the human endometrium
(15) and primary human EVT (16, 17). IL11 withdrawal alleviated
IL11-induced STAT3 activation, supporting that IL11 likely regulates
placentation in vivo at least in part via STAT3. To confirm this, use of
STAT3 inhibitor or gene silencing studies should be performed.
Control IL11 
D
BA
 le
ct
in
 p
os
iti
ve
 
do
ub
le
 n
uc
le
i c
el
ls
/fi
el
d
Control IL11
0
1
2
3
4 *
D
BA
 le
ct
in
 p
os
iti
ve
 
ce
lls
/fi
el
d
Control IL11 
0
20
40
60
80
100 ****
Control IL11 
Control IL11 
0
50
100
150
%
 O
ut
gr
ow
th
 (a
rb
itr
ar
y 
un
its
)
**
Ligand Scr
siRNA knockdown
PAPPA2
** **
C   IL11  PAPPA2    C   IL11       C   IL11
0
1
2
3
4
Stroma    CT          ST
In
te
ns
ity
 S
co
re
 ***
0
1
2
3
In
te
ns
ity
 S
co
re
Placenta      Decidua
**
**
PA
P
PA 2 
PA
P
PA
2 
D
B
A 
Le
ct
in
 
Control PAPPA2 
Co
ntr
ol 
HI
F1
A
FL
T1
PA
PP
A2 IG
F1 IL1
5
IL1
0
IL1
8
-4
-2
0
2
4
Fo
ld
 C
ha
ng
e 
Fr
om
 C
on
tro
l (
R
Q
)
**
***
*
** **
*** ***
Control 
 IL11
0
200
400
600
800
Se
ru
m
 IG
F-
1 
(p
g/
m
l)
NP           E13         E17
*
A B
GDC
E F H
J KI
Fig. 2. IL11 impairs IGF1 and up-regulates pappasylin-A2 (PAPPA2) in mouse
and human placenta to alter EVT function and alters decidual uNK cells.
(A) Effects of single-dose IL11 treatment (500 μg/kg), after 2 h, onmouse placental
gene expression at E13, normalized to control, from highest to lowest abun-
dance quantified by real-time PCR array; n = 3. (B) Circulating IGF1 levels were
quantified by ELISA in mouse sera. Data are mean ± SEM, one-way ANOVA, *P <
0.05, n = 5. (C) PAPPA2 immunostaining shows increased placental and decidual
levels following IL11 administration in E8 through E13 treated mouse embryo
sections. Inset is negative control. (Scale bar: 500 μm.) (D) Data are mean ± SEM,
Students t test, *P < 0.05, **P < 0.01, n = 5. (E) First-trimester human placental
villous explants cultured with saline or IL11 (100 ng/mL) for 48 h were immunos-
tained for PAPPA2 or negative control IgG (Inset). (Scale bar: 200 μm.) (F) PAPPA2
levels were increased in the syncytiotrophoblast (arrows). Data are mean ±
SEM, Students t test, ***P < 0.001, n = 5. (G) Representative images of first-
trimester human placental villous explants cultured on collagen drops to model
villous outgrowth and invasion. (Scale bar: 500 μm.) (H) Treatment with
recombinant human PAPPA2 (100 ng/mL) or IL11 (100 ng/mL) similarly reduced
trophoblast outgrowth compared with saline vehicle control. PAPPA2 knock-
down by siRNA rescued IL11-impaired EVT outgrowth. Data are mean ± SEM,
ANOVA, Tukey’s post hoc, **P < 0.01, n = 5. (I) Dolichos biflorus agglutinin (DBA)
lectin staining highlights decidual uNK cells in E13 implantation sites (Top), and
high-power images show double-nuclei uNK cells in IL11-treated implantation
sites (Bottom). (Scale bar: Top, 100 μm; Bottom, 50 μm.) (J) Decidual uNK cells and
(K) double-nuclei uNK cells were quantified expressed as number of positive cells
per field (20× magnification; three fields per tissue were analyzed from three
placentas per mouse). Data are mean ± SEM, Students t test, ***P < 0.0001, n = 5. IS
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Fig. 3. IL11 withdrawal at mid gestation rescues PE features in mice. Pregnant
mice were treated with IL11 (500 μg·kg−1·d−1) from E10 through E14 (IL11
withdrawal), n = 8. (A) In the IL11 withdrawal treatment group, SBP was reduced
at late gestation (E16 through E17); (B) total urinary protein was reduced and (C)
fetal weight (E17) was significantly increased at late gestation compared with
IL11-treated mice from E10 through E17. Data are mean ± SEM, one-way
ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001, ***P < 0.0001, n = 8. (D) E17
embryo sections were stained for trophoblasts (cytokeratin; red) or smooth
muscle (α-SMA; green) (Top), hematoxylin and eosin H&E (Middle), and isolectin
B4 (Bottom). Insets are negative controls. (Scale bar:50 μm.) (E) Decidual vessel
area was measured in cross sections from three placentas per mouse at E17. Data
are mean ± SEM, one-way ANOVA, **P < 0.01, n = 8. (F) IL11 withdrawal rescues
IL11-impaired vascular branching in the placental labyrinth, one-way ANOVA,
**P < 0.01, n = 8. (G) IL11 withdrawal altered placental growth factor (PLGF) and
follistatin-like-3 (FSTL3) placental gene expression when normalized to IL11
treated placenta at E17, quantified by real-time PCR array, n = 3.
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Although it is established that IL11 regulates human EVT
function (16), previously, the mechanism of IL11-impaired tro-
phoblast invasion and a potential causative role of IL11 in the
development of PE were unknown. IL11 did not regulate com-
mon proteases associated with human EVT invasion and PE,
including matrix metallopeptidases, tissue inhibitors of matrix
metallopeptidases, plasminogen activator urokinase, plasminogen
activator urokinase receptor, and serpin peptidase inhibitors (16).
We have now identified that IL11 significantly up-regulates
PAPPA2 in the human and mouse placenta and also circulating
levels in pregnant mice. The functional role of PAPPA2 in EVT
invasion has not previously been investigated. We demonstrated
that PAPPA2 ligand impaired primary human EVT outgrowth, and
PAPPA2 knockdown was able to rescue IL11-impaired EVT out-
growth, implying that IL11 impedes trophoblast invasion, at least
partly via PAPPA2. This demonstrates a novel mechanism by which
IL11 impairs trophoblast invasion and spiral artery remodeling.
Additionally, we have shown that IL11 alters decidual immune
cells required for normal spiral artery remodeling. IL10, among
other factors, can induce M2 antiinflammatory macrophage
polarization, which promotes tissue remodeling and immune
tolerance (35). In the IL11-treated mouse placenta, IL10 was
significantly down-regulated, suggesting that IL11 may promote
M2 macrophage polarization. Although total macrophages were
not altered in the IL11-treated mouse decidua, the polarization
status was not investigated. Interestingly, IL10 is also reduced in
women with PE (36). Uterine natural killer cells are the most
abundant immune cell type at the maternal−fetal interface (27).
IL11 significantly reduced placental IL15, required for uNK cell
maturation and differentiation (37), and IL18, secreted by uNKs
to mediate normal tissue remodeling (38). In accordance, de-
cidual uNK cell numbers were reduced in IL11-treated pregnant
mice at mid-gestation. Binucleate uNK cells, representing se-
nescent cells (39), were also significantly increased. This finding
contradicts a previous report on IL11Rα−/− mice, in which IL15
production was compromised and uNK cell localization within
the decidual compartment was virtually absent (40). Together,
these findings suggest that IL11 signaling is required for normal
uNK cell recruitment, but elevated levels also affect recruitment
and/or differentiation and normal function. Our findings high-
light a complex role for IL11 in impairing spiral artery remod-
eling, possibly attributed to impaired immune cell recruitment
and/or differentiation.
IL11 withdrawal after the development of PE features in mice
alleviated elevations in blood pressure and proteinuria and also
reduced fetal weight. Differences in placental labyrinth mor-
phology were evident in the IL11 withdrawal group compared
with IL11-treated mice at E17, proposing that this layer is dy-
namic during late gestation. IL11 did not alter the expression of
syncytialization genes or hCG in the human or mouse placenta,
suggesting that IL11 does not affect syncytialization. Thus,
functionally, the precise mechanism of restored placental func-
tion remains to be investigated. Impaired labyrinth branching
and structure in IL11-treated placenta was restored in the IL11
withdrawal placenta, implying that rescue of the labyrinth may
mediate reduced blood pressure and proteinuria. Labyrinth de-
fects alone have been shown to induce hypertension in mice (41).
This finding could potentially be attributed to a significant in-
crease in placental growth factor (PLGF) in the IL11 withdrawal
compared with IL11-treated mouse placenta at E17. Inducing
PLGF has been shown to ameliorate PE symptoms in mice (42),
indicating a potential mechanism by which alleviating high levels
of IL11 could rescue PE features in vivo in our model.
Clinically diagnosed most often in the late second or third
trimester, the only currently available treatment for PE is pla-
cental delivery by labor induction or Cesarian section. Therefore,
identification of biomarkers in early stages of PE could help to
target women at elevated risk for closer follow-up, optimizing
delivery timing, and avoiding unnecessary premature deliveries.
In this study, we provide evidence that circulating IL11 was
significantly increased in women with EO PE. Screening in a
large-scale cohort could determine the value of IL11 as a po-
tential biomarker to predict PE. IL11 protein was also signifi-
cantly increased in human PE villous and EVT. This supports a
previous study demonstrating increased decidual IL11, but con-
tradicts reported unchanged IL11 levels in EVT in PE at term,
relative to gestation matched controls (20), likely due to pop-
ulation and/or methodological differences.
Despite its well-characterized role in decidualization in hu-
mans and mice, IL11 withdrawal had no effect on the decidua,
confirming our previous findings that IL11 is required early
postimplantation in decidua formation (28). In women and mice,
decidual IL11Rα protein levels are significantly reduced during
the second trimester or mid-gestation, respectively, highlighting
the potential feasibility for targeting IL11 to ameliorate PE in
women, without affecting the decidua or pregnancy viability.
In summary, this is the first study, to our knowledge, to
demonstrate that IL11 is causal of PE features in a mouse model
and likely in women. These findings highlight the potential of
IL11 inhibition to rescue PE symptoms in women. We have
established an appropriate model to test potential therapeutics
for the treatment of PE, of which there are few that have all
these features.
Materials and Methods
Nonpregnant or pregnant female mice were injected with recombinant
human IL11 (500 μg·kg−1·d−1, i.p.) or saline control from E8-13, or E10-17. To
normalize IL11 levels, mice were i.p. injected with IL11 from E10 through E14
(IL11 withdrawal). SBP was measured by tail cuff plethysmography. Total
urinary protein was quantified by Bradford colorimetric protein assay. Kid-
ney glomerular morphology was assessed by electron microscopy. Placental
tissue sections were stained with hematoxylin and eosin or Masson’s tri-
chrome or immunostained with antibodies against vimentin, cytokeratin,
α-SMA, pSTAT3, IL11, or IL11Rα. Mouse Preeclampsia qPCR-Arrays (QIAGEN)
were performed on placental RNA. Targets were validated in human and
mouse placental tissue by qPCR (Table S2), immunohistochemistry and
Western blot. Human first-trimester explants were cultured with IL11
Fig. 4. IL11 levels are elevated in the sera of women before onset of PE. IL11
protein was quantified in pregnant human serum using ELISA (A) during the first
or second trimester, before the development LO or EO PE, or (B) after PE onset.
Data are expressed as mean ± SEM, Mann−Whitney u test, *P < 0.05, **P < 0.01,
**P < 0.001, n = 15. (C) IL11 and IL11Rα mRNA levels in PE placental villous or
preterm match control villous whole tissue were determined by quantitative real-
time PCR, normalized to 18S, and expressed as mean delta-delta cycle threshold
(ddCT) values ± SEM, Students t test, n = 15. (D) IL11 protein levels in PE placental
villous or preterm match controls were determined by immunohistochemistry.
Inset is negative control. (Scale bar: 50 μm.) (E) Staining intensity in the syncy-
tiotrophoblast (ST) (arrow heads), cytotrophoblast (CT), and stroma were scored
from 0 (no staining) to 3 (intense staining) by two independent, blinded assessors.
Data expressed as mean ± SEM, Students t test, **P < 0.01, n = 15.
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(100 ng/mL), PAPPA2 (100 ng/mL), or PBS. PAPPA2 knockdown was performed
by siRNA, and EVT outgrowth was measured using Adobe Photoshop. IL11
levels in human blood and placental tissue samples were measured using ELISA
and immunohistochemistry, respectively. All animal procedures were ap-
proved by the Monash Medical Centre (B) Animal Ethics Committee, and this
study followed the National Health and Medical Research Council (NHMRC)
Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes. Human blood collections were approved by the ethical committee
of the University of Tokyo and Mushashino Red Cross Hospital, with in-
formed written consent obtained from all women. Human placenta ethics
approval was granted by the Southern Health Human Research and Ethics
committee. Informed consent was obtained from all participating patients.
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